TSG is developing drug candidates that attack the lipid envelope target, demonstrating potent antiviral results against diverse classes of viruses. TSG’s lead drug candidate is modeled after viral-encoded amino acid sequences. It has demonstrated potent antiviral activity against viruses less than 200 nanometers in size. It selectively forms pores in highly curved membranes but they do not affect larger, low-curvature membrane structures such as human cells.

Results of the laboratory tests have suggested that the TSG’s peptides have efficacy against flaviviruses such as Dengue, Zika, Yellow Fever, Japanese Encephalitis, as well as representative alphavirus (Chikungunya), filoviruses (Ebola), rhabdovirus (Rabies), and coronavirus (Mouse Hepatitis) species.